Clinical Trials
Friday, July 26th, 2013
STROKEAHA: July 18, 2013 Background and Purpose—Unilateral and bilateral training protocols for upper limb rehabilitation after stroke represent conceptually contrasting approaches with the same ultimate goal. In a randomized controlled trial, we compared the merits of modified constraint-induced movement therapy, modified bilateral arm training with rhythmic auditory cueing, and a dose-matched conventional treatment. Modified constraint-induced movement […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: July 2, 2013 As the nation’s primary supporter of basic and clinical stroke research, the National Institute of Neurological Disorders and Stroke (NINDS) strives to pursue the most pressing and promising scientific opportunities. During the past decade, NINDS has led a stroke planning effort performed by the Stroke Progress Review Group (PRG), an external group […]
Clinical Trials
Friday, July 26th, 2013
STROKEAHA: June 20, 2013 Background and Purpose—In the German Multicenter Erythropoietin (EPO) Stroke Trial, patients not receiving thrombolysis most likely benefited from EPO on clinical recovery, whereas a combination of rtPA and EPO was associated with increased mortality. We investigated whether the combination of rtPA and EPO increased release of the endogenous NO synthase inhibitor asymmetric […]
Clinical Trials
Thursday, July 18th, 2013
CIRCULATIONAHA: July 16, 2013 Background—The role of concomitant aspirin therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed concomitant aspirin use and its association with clinical outcomes among AF patients treated with OAC. Methods and Results—The Outcomes Registry for Better Informed Treatment (ORBIT) of Atrial Fibrillation registry enrolled 10,126 AF […]
Clinical Trials
Thursday, July 18th, 2013
The Lancet Neurology: July 12, 2013 Background Findings from randomised trials have shown a higher early risk of stroke after carotid artery stenting than after carotid endarterectomy. We assessed whether white-matter lesions affect the perioperative risk of stroke in patients treated with carotid artery stenting versus carotid endarterectomy. Read more
Clinical Trials
Thursday, July 18th, 2013
STROKEAHA: 7/11/13 Background and Purpose—Since Food and Drug Administration approval of intravenous tissue-type plasminogen activator (tPA) for treatment of acute ischemic stroke in 1996, it has become clear that several criteria used for exclusion from therapy were not based on actual data or operationally defined for use in clinical practice. All eligibility criteria from […]
Clinical Trials
Thursday, July 18th, 2013
Plosone: 7/9/13 In an effort to understand how results of human clinical trials are made public, we analyze a large set of clinical trials registered at ClinicalTrials.gov, the world’s largest clinical trial registry. Materials and Methods We considered two trial result artifacts: (1) existence of a trial result journal article that is formally linked to a registered […]
Clinical Trials
Thursday, July 18th, 2013
CIRCULATIONAHA: 6/14/13 Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran […]
Clinical Trials
Monday, July 15th, 2013
FOR IMMEDIATE RELEASE Contact: Gretchen C. Wartman Monday, July 08, 2013 Telephone: 202-223-7560 The National Minority Quality Forum (The Forum) announces that the Pharmaceutical Research and Manufacturers of America (PhRMA) has joined The Forum’s collaboration with Microsoft to launch The National Clinical Trial Network (NCTN). PhRMA represents the country’s leading innovative biopharmaceutical research and […]
Clinical Trials
Monday, July 15th, 2013
Thrombosis Journal: 6/28/2013 Results of clotting tests used to measure the effect of old and new antithrombotic drugs can be expressed in different ways and this is considered as one of the sources of variability to explain the differences of results obtained for the same patient plasma when tested in different laboratories. This is particularly important […]
